BioCardia Inc. (BCDA)
BioCardia Inc. (BCDA) Stock Price, Analysis & Data
| Bid | n/a |
| Market Cap | n/a |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -7.78M |
| Beta | 0.49 |
| EPS (ttm) | n/a |
| PE Ratio (ttm) | n/a |
| Forward PE | -1.62 |
| P/B (ttm) | 11.33 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | n/a |
| Volume | NaN |
| Avg. Volume (20D) | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a - n/a |
| 52-Week Range | n/a - n/a |
| Analyst | Strong Buy |
| Price Target | 15.5 (NaN%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About BCDA
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also ...
Financial Performance
In 2025, BioCardia's revenue was 0, a decrease of -100% compared to the previous year's 58K. Earnings were -8.23M, an increase of 3.55%.
Financial StatementsAnalyst Forecast
According to 2 analyst ratings, the average rating for BCDA stock is "Strong Buy". The 12-month stock price forecast is 15.5, which is downside of NaN% from the latest price.
Stock Forecasts
